<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		n/a
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	res (malcate where provided, section/paragraph)	n/a
Provide accession number in repository OR		11/ 0
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		n/a
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		n/a
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		,
Animal observed in or captured from the		n/a
field: Provide species, sex and age where possible		
Model organisms: Provide Accession number		n/a
in repository (where relevant) OR RRID		II/d
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		n/a
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		n/a
accession number if available, and source		
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		11/ a
equivalent committee(s), provide reference number	Page 4 : Patient selection	
for approval.		
Provide statement confirming informed consent	Page 4 : Patient selection	
obtained from study participants.	rage + . ralient selection	

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	Page 4 : Patient selection	
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	res (indicate where provided, section) paragraphy	n/a
by-step protocols are available.		ny a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	Page 5: Statistical analysis	
done, or if they were not carried out.	,	
Sample size determination	Page 4 : Patient selection	
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria	Page 4 : Patient selection	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		n/a
replicated in laboratory		
Define whether data describe technical or biological		n/a
replicates		
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Page 4 : Patient selection	
authority granting ethics approval (IRB or equivalent		
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details		n/a
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		n/a
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		n/a
state the authority granting approval and reference		
number for the regulatory approval		1

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were	Page 4 : Patient selection	
determined and specified in advance.		
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Page 5: Statistical analysis	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a
If data are publicly available, provide accession number in repository or DOI or URL.		n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		, .
State whether the code or software is available.		n/a
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,		n/a
ARRIVE) have been followed, and whether a checklist		
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/tau-20-1096